2.41
price up icon1.26%   0.03
after-market アフターアワーズ: 2.47 0.06 +2.49%
loading

Aptevo Therapeutics Inc (APVO) 最新ニュース

pulisher
Mar 13, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short Interest - Defense World

Mar 13, 2025
pulisher
Mar 13, 2025

APVO stock plunges to 52-week low of $2.48 amid steep annual decline - Investing.com Australia

Mar 13, 2025
pulisher
Mar 12, 2025

APVO stock plunges to 52-week low of $2.48 amid steep annual decline By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 10, 2025

Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga

Mar 10, 2025
pulisher
Mar 06, 2025

Aptevo to Participate in March Conferences - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 06, 2025

Can These Two Major Biotech Conferences Unlock Aptevo's Next Growth Phase? - StockTitan

Mar 06, 2025
pulisher
Mar 04, 2025

APVO stock plunges to 52-week low, touches $3 mark - Investing.com

Mar 04, 2025
pulisher
Mar 04, 2025

APVO stock plunges to 52-week low, touches $3 mark By Investing.com - Investing.com South Africa

Mar 04, 2025
pulisher
Mar 03, 2025

Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Aptevo Therapeutics (APVO) Projected to Post Quarterly Earnings on Tuesday - Defense World

Mar 02, 2025
pulisher
Feb 28, 2025

Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 21, 2025

Roth Capital Brokers Decrease Earnings Estimates for APVO - Defense World

Feb 21, 2025
pulisher
Feb 20, 2025

FY2029 Earnings Estimate for APVO Issued By Roth Capital - Defense World

Feb 20, 2025
pulisher
Feb 16, 2025

Aptevo Therapeutics files $100M mixed securities shelf - MSN

Feb 16, 2025
pulisher
Feb 15, 2025

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

Feb 15, 2025
pulisher
Feb 15, 2025

Exclusive: Aptevo's Revolutionary Cancer Treatment Achieves 100% Remission RateCEO Interview Alert - StockTitan

Feb 15, 2025
pulisher
Feb 14, 2025

Aptevo Therapeutics Inc. (APVO) reports earnings - Quartz

Feb 14, 2025
pulisher
Feb 14, 2025

Aptevo Therapeutics Inc. SEC 10-K Report - TradingView

Feb 14, 2025
pulisher
Feb 14, 2025

Aptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last year - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update - StockTitan

Feb 14, 2025
pulisher
Feb 14, 2025

APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025 - ACCESS Newswire

Feb 13, 2025
pulisher
Feb 13, 2025

APVO stock plunges to 52-week low at $3.62 amid steep annual decline By Investing.com - Investing.com South Africa

Feb 13, 2025
pulisher
Feb 13, 2025

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding - ACCESS Newswire

Feb 13, 2025
pulisher
Feb 12, 2025

Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale - ACCESS Newswire

Feb 12, 2025
pulisher
Feb 11, 2025

Aptevo Therapeutics Showcases Promising Oncology Drug Pipeline - TipRanks

Feb 11, 2025
pulisher
Feb 08, 2025

TG Therapeutics (NASDAQ:TGTX) vs. Aptevo Therapeutics (NASDAQ:APVO) Head-To-Head Review - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire

Feb 07, 2025
pulisher
Feb 06, 2025

Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements - ACCESS Newswire

Feb 06, 2025
pulisher
Jan 29, 2025

Aptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Decline in Short Interest - Defense World

Jan 29, 2025
pulisher
Jan 27, 2025

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire

Jan 27, 2025
pulisher
Jan 26, 2025

Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 25, 2025

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 24, 2025

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Aptevo Therapeutics Announces Closing of $2.75 Million Offering - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 24, 2025

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update - ACCESS Newswire

Jan 24, 2025
pulisher
Jan 21, 2025

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering - ACCESS Newswire

Jan 21, 2025
pulisher
Jan 15, 2025

Aptevo's Senior Director to Present ADAPTIR Platform at Major Biotech Conference PepTalk 2025 - StockTitan

Jan 15, 2025
pulisher
Jan 12, 2025

Trend Tracker for (APVO) - Stock Traders Daily

Jan 12, 2025
pulisher
Jan 10, 2025

Are Medical Stocks Lagging Aptevo Therapeutics (APVO) This Year? - Yahoo Finance

Jan 10, 2025
pulisher
Dec 15, 2024

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish - MSN

Dec 15, 2024
pulisher
Dec 14, 2024

APVO stock touches 52-week low at $5.1 amid sharp annual decline - Investing.com Australia

Dec 14, 2024
pulisher
Dec 13, 2024

Aptevo Therapeutics Inc. Announces 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline Aml Trial - Marketscreener.com

Dec 13, 2024
pulisher
Dec 12, 2024

Aptevo reports full remission in AML trial - Investing.com India

Dec 12, 2024
$307.24
price up icon 0.61%
$76.55
price up icon 1.97%
$32.77
price up icon 0.28%
$20.79
price up icon 8.34%
$99.47
price up icon 2.06%
biotechnology ONC
$259.19
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):